ArticleFrontiers in pharmacology2025

Net health benefit of mavacamten for the treatment of Chinese patients with obstructive hypertrophic cardiomyopathy: a model-based economic evaluation.

Han Bao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.